Your browser is no longer supported. Please, upgrade your browser.
Settings
CLSD Clearside BioMedical, Inc. daily Stock Chart
CLSD [NASD]
Clearside BioMedical, Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own- Shs Outstand25.50M Perf Week12.88%
Market Cap201.19M Forward P/E- EPS next Y-2.24 Insider Trans- Shs Float21.83M Perf Month0.51%
Income-25.90M PEG- EPS next Q-0.43 Inst Own47.10% Short Float4.07% Perf Quarter-12.33%
Sales0.50M P/S402.39 EPS this Y-13.70% Inst Trans49.32% Short Ratio4.46 Perf Half Y-52.61%
Book/sh1.82 P/B4.34 EPS next Y-10.30% ROA-48.00% Target Price21.25 Perf Year-
Cash/sh3.28 P/C2.41 EPS next 5Y- ROE-84.50% 52W Range5.44 - 25.08 Perf YTD-11.74%
Dividend- P/FCF- EPS past 5Y- ROI-31.80% 52W High-68.54% Beta-
Dividend %- Quick Ratio15.60 Sales past 5Y- Gross Margin- 52W Low45.04% ATR0.63
Employees23 Current Ratio15.60 Sales Q/Q- Oper. Margin- RSI (14)58.26 Volatility6.83% 9.19%
OptionableNo Debt/Eq0.00 EPS Q/Q6.90% Profit Margin- Rel Volume1.67 Prev Close7.56
ShortableYes LT Debt/Eq0.11 EarningsMar 14 BMO Payout- Avg Volume199.43K Price7.89
Recom1.60 SMA207.56% SMA504.33% SMA200-26.22% Volume332,295 Change4.37%
Feb-24-17Initiated JP Morgan Overweight $19
Nov-10-16Reiterated Needham Buy $16 → $24
Oct-24-16Reiterated Stifel Buy $13 → $23
Mar-28-17 08:30AM  Clearside Biomedical, Inc. to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-23-17 01:04PM  CLEARSIDE BIOMEDICAL, INC. Financials
Mar-16-17 04:43PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 10-K, Annual Report +11.38%
Mar-14-17 07:46AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -12.72%
07:30AM  Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Clearside Biomedical Inc Earnings Release - 07:00 am ET
Mar-08-17 09:22AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-07-17 04:30PM  Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017 Conference Call to Follow GlobeNewswire -7.65%
Mar-01-17 05:00PM  Clearside Biomedical, Inc. to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire +7.64%
08:00AM  Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent GlobeNewswire
Feb-27-17 08:55AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib +7.20%
08:00AM  Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program GlobeNewswire
Feb-24-17 07:11AM  Coverage initiated on Clearside Biomedical by JP Morgan +16.81%
Feb-16-17 07:30AM  Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion GlobeNewswire
Jan-25-17 09:21AM  Biotech Premarket Movers: Pacira, Clearside Biomedical and Organovo +5.04%
Jan-05-17 04:30PM  Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent GlobeNewswire
07:30AM  Clearside Biomedical, Inc. to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-17 04:30PM  Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer GlobeNewswire +5.34%
Jan-03-17 09:05AM  Clearside BioMedical (CLSD) is Oversold: Can It Recover?
Dec-23-16 09:21AM  How Clearside (CLSD) Stock Stands Out in a Strong Industry
Dec-14-16 04:15PM  Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-12-16 05:04AM  Is Ares Commercial Real Estate Corp (ACRE) A Good Stock To Buy? at Insider Monkey
Dec-09-16 10:15AM  Clearside Biomedical Closes in on Secondary Offering -21.94%
09:20AM  Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire
Dec-08-16 10:15AM  Clearside Biomedical Prices Secondary Offering -20.10%
Dec-07-16 04:02PM  Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock GlobeNewswire
Dec-01-16 10:54AM  ETFs with exposure to Clearside Biomedical, Inc. : December 1, 2016
Nov-30-16 10:25AM  Clearside Biomedical Gears Up for Secondary Offering -20.91%
07:34AM  Clearside Biomedical, Inc. breached its 50 day moving average in a Bearish Manner : CLSD-US : November 30, 2016
Nov-23-16 04:04PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Nov-15-16 08:24AM  Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata in Diabetic Macular Edema GlobeNewswire
Nov-14-16 04:10PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 10-Q, Quarterly Report +5.85%
Nov-09-16 09:33AM  Clearside Biomedical reports 3Q loss +5.98%
08:30AM  Clearside Biomedical Inc Earnings Call scheduled for 8:30 am ET today
08:11AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q3 2016 Clearside Biomedical Inc Earnings Release - 07:00 am ET
07:00AM  Clearside Biomedical, Inc. Announces Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-16 04:30PM  Clearside Biomedical, Inc. to Present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016 GlobeNewswire
07:00AM  Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development GlobeNewswire
Nov-02-16 07:00AM  Clearside Biomedical, Inc. to Report Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 9, 2016 GlobeNewswire -20.22%
Oct-11-16 02:33PM  Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016
Oct-10-16 07:00AM  Clearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting GlobeNewswire +5.61%
Oct-04-16 04:07PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
Sep-20-16 04:30PM  Clearside Biomedical, Inc. to Present at the 2016 Ladenburg Thalmann Healthcare Conference GlobeNewswire +5.46%
Aug-28-16 10:52PM  SINA, 58.com Among Billionaire Lei Zhangs Big Purchases in Q2 at Insider Monkey
Aug-12-16 04:29PM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 10-Q, Quarterly Report
Aug-11-16 07:18AM  CLEARSIDE BIOMEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an +6.20%
07:00AM  Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results GlobeNewswire
Aug-10-16 07:00AM  Clearside Biomedical, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-04-16 07:00AM  Clearside Biomedical, Inc. to Report Second Quarter 2016 Financial Results GlobeNewswire
Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHAFFER CHRISTY LDirectorMar 20Buy6.902,20015,1802,200Mar 22 05:14 PM
Cagle Gerald D.DirectorMar 16Buy6.845,00034,20010,941Mar 20 05:23 PM
Thorp ClayDirectorMar 16Sale6.7721,485145,4534,057,364Mar 17 04:19 PM
Thorp ClayDirectorMar 15Sale6.4747,000304,0904,078,849Mar 17 04:19 PM
Thorp ClayDirectorFeb 22Sale7.492,00014,9804,125,849Feb 22 04:36 PM
Thorp ClayDirectorFeb 21Sale7.5525,000188,7504,127,849Feb 22 04:36 PM
Thorp ClayDirectorFeb 17Sale7.5410,00075,4004,152,849Feb 17 07:32 PM
Thorp ClayDirectorFeb 16Sale7.5814,000106,1204,162,849Feb 17 07:32 PM
Thorp ClayDirectorFeb 15Sale7.6417,485133,5854,176,849Feb 17 07:32 PM
Thorp ClayDirectorJan 20Sale7.778,00062,1604,194,334Jan 20 08:19 PM
Hatteras Venture Advisors III,May be part of a 13(d) GroupJan 19Sale8.226,47853,2491,757,719Jan 19 05:53 PM
Thorp ClayDirectorJan 19Sale8.2315,485127,4424,202,334Jan 20 08:19 PM
Hatteras Venture Advisors IV SMay be part of a 13(d) GroupJan 19Sale8.227,59262,4062,060,514Jan 19 07:31 PM
Hatteras Venture Advisors III,May be part of a 13(d) GroupJan 18Sale8.6410,45790,3481,764,197Jan 19 05:53 PM
Thorp ClayDirectorJan 18Sale8.6425,000216,0004,217,819Jan 20 08:19 PM
Hatteras Venture Advisors IV SMay be part of a 13(d) GroupJan 18Sale8.6412,258105,9092,068,106Jan 19 07:31 PM
Hatteras Venture Advisors III,May be part of a 13(d) GroupJan 17Sale8.928,36674,6251,774,654Jan 19 05:53 PM
Thorp ClayDirectorJan 17Sale8.9220,000178,4004,242,819Jan 20 08:19 PM
Hatteras Venture Advisors IV SMay be part of a 13(d) GroupJan 17Sale8.929,80687,4702,080,364Jan 19 07:31 PM